44 86

Cited 0 times in

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

 Shanu Modi  ;  Cristina Saura  ;  Toshinari Yamashita  ;  Yeon Hee Park  ;  Sung-Bae Kim  ;  Kenji Tamura  ;  Fabrice Andre  ;  Hiroji Iwata  ;  Yoshinori Ito  ;  Junji Tsurutani  ;  Joohyuk Sohn  ;  Neelima Denduluri  ;  Christophe Perrin  ;  Kenjiro Aogi  ;  Eriko Tokunaga  ;  Seock-Ah Im  ;  Keun Seok Lee  ;  Sara A Hurvitz  ;  Javier Cortes  ;  Caleb Lee  ;  Shuquan Chen  ;  Lin Zhang  ;  Javad Shahidi  ;  Antoine Yver  ;  Ian Krop 
 NEW ENGLAND JOURNAL OF MEDICINE, Vol.382(7) : 610-621, 2020-02 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized / administration & dosage* ; Antibodies, Monoclonal, Humanized / adverse effects ; Antineoplastic Combined Chemotherapy Protocols / adverse effects ; Antineoplastic Combined Chemotherapy Protocols / therapeutic use* ; Breast Neoplasms / drug therapy* ; Breast Neoplasms / mortality ; Breast Neoplasms / pathology ; Camptothecin / administration & dosage ; Camptothecin / adverse effects ; Camptothecin / analogs & derivatives* ; Consolidation Chemotherapy ; Female ; Humans ; Immunoconjugates / administration & dosage* ; Immunoconjugates / adverse effects ; Intention to Treat Analysis ; Kaplan-Meier Estimate ; Lung Diseases, Interstitial / chemically induced* ; Middle Aged ; Progression-Free Survival ; Receptor, ErbB-2 / analysis ; Receptor, ErbB-2 / antagonists & inhibitors* ; Trastuzumab
In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines of therapy. The drug was associated with myelosuppression and gastrointestinal toxicity; interstitial lung disease was reported in 13.6% of the patients. Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. Methods In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. Results Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). Conclusions Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, .)
Files in This Item:
T9992020494.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.